Investor relations
Information for professional investors
FOSCA BioTech is an early-stage biotechnology company developing a patented immunotherapy device for solid tumours. Further information is available to professional investors on request.
Why FOSCA
What stands behind the company
01
A patented approach
Patent applications have been filed for the technology.
02
Multi-target by design
Single-target therapies leave other immunosuppressive pathways open, which leads to resistance. The FOSCA device removes multiple cancer-promoting molecules at the same time.
03
Validated in vitro, in pre-clinical testing
The approach has been validated in vitro and the device is currently in pre-clinical testing.
04
Experienced founding team
A founder with a PhD in cancer biology and over 10 years of research in molecular targeting, alongside 20+ years of commercial and operational leadership.
05
Institutional support
Supported by Bpifrance, France 2030, La French Tech, Université de Bordeaux and Université Grenoble Alpes.
Investor deck
Request the investor deck
The deck is shared on request only. Each request is reviewed by our team before we respond.
This page is for information only and does not constitute an offer or solicitation of any kind.